AXA Alternative Investments
VC Fund
AXA Alternative Investments is a VC fund focused on Health Care and Biotechnology. AXA IM Alts' strategies are based on strong convictions, with the goal of providing long-term value to customers, communities, and the world. AXA IM Alts is part of AXA Investment Managers.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries AXA Alternative Investments invests in
Stages AXA Alternative Investments invests in
Countries AXA Alternative Investments invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Life Science 2 (33%)
- Environmental Consulting 2 (33%)
- Forestry 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Series C 1 (17%)
- Funding Round 1 (17%)
Country
- United States 3 (50%)
- Kenya 1 (17%)
- Brazil 1 (17%)
- Switzerland 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Gibbon
Natural Capital Investment Lead
|
Natural Capital Investment Lead | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Imbria Pharmaceuticals
|
Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. Weare propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do. | Series B / Nov 17, 2025 | |
Chloris Geospatial
|
Chloris Geospatial is able to provide answers today to critical natural capital issues. Chloris Geospatial provides innovative measurements of natural capital that use cutting-edge remote sensing, machine learning, and ecological science. | $14.8M / Series A / Jun 30, 2025 | |
ReproNovo
|
ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M / Series A / May 21, 2025 | |
Mombak
|
Mombak is a carbon removal company that focuses on the reforestation of the Amazon. The company's team combines experts in science, technology, forestry, and carbon markets | $30M / Series A / Apr 29, 2025 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
Sistema.bio
|
Sistema.bio is a hybrid reactor biodigester that transforms the manure of animals into biogas and a potent, natural fertilizer. By inputting the manure in the system on a daily basis, you will be able to develop and grow your activities on the farm, improve your energy security, and protect the environment. Transforming your animals’ manure intoresource will provide you with a better quality of life! | $15M / Oct 14, 2024 |
Co-Investors
M Ventures
2 deals together
Alpha Wave Ventures
1 deal together
ALSA Ventures
1 deal together
AN Ventures
1 deal together
Aphelion Capital
1 deal together
At One Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does AXA Alternative Investments invest in?
AXA Alternative Investments invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AXA Alternative Investments?
Public channels for AXA Alternative Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AXA Alternative Investments?
The team at AXA Alternative Investments includes Adam Gibbon (Natural Capital Investment Lead). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
